LIPS is a multicentre ( United Kingdom ) , double-blind , randomised parallel group , placebo-controlled trial , designed to evaluate the efficacy , safety , and tolerability of intravenous immunoglobulin ( IVIg ) @ g/kg plus standard treatment , versus matched placebo plus standard treatment in @ patients with longstanding complex regional pain syndrome .